EGFR and lung carcinoma: Taken together, our findings suggest that more work is needed to evaluate the nature of rare EGFR variants in lung cancer and that JAKis may represent a new strategy to inhibit rare variants of EGFR that do not respond to EGFR‐targeted TKIs.